Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice
- 1 January 1992
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 119 (1), 41-45
- https://doi.org/10.1007/bf01209486
Abstract
Summary We have previously shown that Balb/c mice immunised against syngeneic monoclonal antibodies (mAbs), so that they have anti-idiotypic responses against those mAbs, will clear the mAbs from the circulation as a result of immune complex formation. We report here that with three separate mAbs, this clearance of complexes can result in toxicity to the animals. This was particularly severe with one mAb (NCRC-2), in some cases leading to death. It was not seen with Fab/c or Fab fragments of NCRC-2. This toxic response could be passively transferred with serum, indicating that it was due to formation of immune complexes or to their subsequent clearance. Treatment of mice with cobra venom factor, to reduce complement levels, reduced clearance of complexes but had no effect on toxicity. The anti-histamine pyrilamine did not reduce toxicity. The anti-histamine pyrilamine did not reduce toxicity. This is one of only a few situations in which an anti-(mouse antibody)response has been reported to be potentially dangerous, and is particularly remarkable since it occurs as a result of such a limited anti-antibody response.This publication has 18 references indexed in Scilit:
- Phase I Study on Human Monoclonal Antibody Against CytomegalovirusJournal of Immunotherapy, 1991
- Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatographyJournal of Immunological Methods, 1991
- Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.Proceedings of the National Academy of Sciences, 1991
- Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenograftsEuropean Journal of Cancer and Clinical Oncology, 1990
- The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in balb/c miceInternational Journal of Cancer, 1989
- Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseasesNuclear Medicine Communications, 1988
- A rat model for imaging the effect of anti mouse antibody responses on the biodistribution of radiolabelled mouse monoclonal antibodiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1988
- Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEACancer Immunology, Immunotherapy, 1987
- Activation of mouse complement by monoclonal mouse antibodiesEuropean Journal of Immunology, 1981
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978